Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MICROSCAP

Financiado

Cerrado

MicroRNA targeting to achieve Systemic Sclerosis Control and Prediction

Systemic Sclerosis (SSc) is a disfiguring disease with high mortality and morbidity, characterized by progressive and uncontrollable fibrosis of the skin and internal organs. There is no successful therapy for SSc resulting in a m... ver más

31/03/2016

UMC UTRECHT

176K€

Presupuesto del proyecto: 176K€

Líder del proyecto

UNIVERSITAIR MEDISCH CENTRUM UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-03-31 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UMC UTRECHT

0.00€ | Lider

Proyectos interesantes

MIRASYS

Medical Technol...

Data Science

149K€ Cerrado

BES-2010-029952

Medical Technol...

Data Science

43K€ Cerrado

ASSYSt

Medical Technol...

Data Science

150K€ Cerrado

deFIBER

Medical Technol...

Biomedical Imag...

1M€ Cerrado

SAF2015-66761-P

Medical Technol...

Data Science

296K€ Cerrado

RTI2018-101332-B-I00

Medical Technol...

Data Science

351K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

UNIVERSITAIR MEDISCH CENTRUM UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 176K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Systemic Sclerosis (SSc) is a disfiguring disease with high mortality and morbidity, characterized by progressive and uncontrollable fibrosis of the skin and internal organs. There is no successful therapy for SSc resulting in a markedly shortened life expectancy, usually less that most cancers. Moreover, SSc diagnosis is very difficult in the early phase of the disease; consequently patient treatment is delayed until skin and/or internal organ involvement is evident and already irreversible. The pathology, therefore, presents an extreme need of both effective therapies and early diagnosis/prognosis markers, in order to treat SSc patients before the development of severe organ complications. The proposed project builds on the unique observation that plasmacytoid dendritic cells (pDC) are dysregulated in the early disease onset of SSc, due to an aberrant microRNA (miRNA) expression pattern. The aim of the proposal is to delineate the critical role of identified miRNAs in pDC dysregulation and translate it to clinical relevant instruments to prevent or treat SSc. Thanks to my scientific and technical expertise in the study of miRNAs and immune regulation, I will be able to dissect the aberrant mechanisms leading to pDC dysregulation via miRNA-regulated pathways. This will provide the basis to develop novel therapeutic approaches to dampen the immune alterations present in SSc and control the disease progression. Furthermore, the analysis of a unique cohort of preclinical SSc cohort present in Radstake’s group and its expertise in SSc field will allow me to identify miRNA profiles that predict the progression of early-SSc into definite SSc. The marriage between my own and Radstake’s group expertise will therefore create the perfect ground to open novel perspectives for a more effective treatment and prevention of SSc, reducing the disease impact on health and the economic resources employed for SSc patients, with an overall advantage for the entire European Community.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores